CELG News 153.03 06/02/2014 04:34:16 Celgene Corp (CELG)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Celgene Corp (CELG) 153.03 $CELG

Post-Hoc Analysis of Overall Survival in Phase III MPACT Study of Patients with Advanced Pancreatic Cancer Presented at ASCO 2014
Business Wire - Sun Jun 01, 8:00AM CDT
Celgene Corporation (NASDAQ: CELG) today announced updated Overall Survival (OS) results from a post-hoc analysis of its phase III MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study of ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in treatment-naive patients with metastatic pancreatic cancer. A poster discussion of the analysis is scheduled for Sunday, June 1st at 11:30 am CT at the 50th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Ill.

Final Glance: Biotechnology companies
AP - Fri May 30, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:

Midday Glance: Biotechnology companies
AP - Fri May 30, 12:19PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:

Early Glance: Biotechnology companies
AP - Fri May 30, 9:29AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:

Biogen Idec
at Investor's Business Daily - Thu May 29, 5:48PM CDT
Biogen Idec (BIIB) rose 4% after JPMorgan upgraded its stock to overweight from neutral, citing positive opinions on oral multiple-sclerosis drug Tecfidera, and hiked its price target to 375 from 300. JPMorgan cut Celgene (CELG) to neutral from...

Scorned Pfizer Should Forget AstraZeneca and Buy Celgene Instead
Todd Campbell, The Motley Fool - Motley Fool - Thu May 29, 5:30PM CDT
AstraZeneca played hard to get and won, at least for now. The British pharmaceutical major this month rejected two nine-figure buyout offers from   Pfizer , which now must wait at least three months before making  any additional offers. ...

Array BioPharma Collaborates with Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 29, 4:10PM CDT
Array BioPharma (ARRY) announced that it has entered into a drug discovery collaboration agreement with Biogen Idec (BIIB).

Biogen Upgraded, Celgene Downgraded On Pipelines
at Investor's Business Daily - Thu May 29, 2:18PM CDT
Big-cap biotechs Biogen Idec (BIIB) and Celgene (CELG) were headed in opposite directions on the stock market today after JPMorgan upgraded one and downgraded the other. JPMorgan analyst Geoff Meacham lifted his rating on Biogen to overweight from...

Stocks Slightly Higher Amid Mixed Data; S&P 500 Logs New High
at Investor's Business Daily - Thu May 29, 9:32AM CDT
Stocks opened modestly higher Thursday despite mixed economic data. The Nasdaq climbed 0.4% to its best levels since early April. The S&P 500 rose 0.2% to a record high. Meanwhile, the Dow Jones industrial average ticked up 0.1%. Volume was tracking...

Veracyte, Foundation Medicine and Panacea Global Paving Way in Faster, More Accurate Cancer Diagnostics
ACCESSWIRE - Thu May 29, 8:53AM CDT
Whitefish, MT / May 29, 2014 / Most of the science behind disease is only truly understandable by scientists, researchers, and physicians rather than the general population. What everyone does understand is that, in virtually every scenario, early detection is a key to treatment or even survivorship. The life sciences IPO boom that started in 2013 has created some additional wind under the sails of few diagnostics companies, including Veracyte Inc. (NASDAQ: VCYT) and Foundation Medicine Inc. (NASDAQ: FMI), and it should have investors taking a closer look at upstart Panacea Global, Inc. (OTCQB: PANG) and its new cancer-detecting technology.

How Will Celgene (CELG) Stock Be Affected By This Analyst Action?
at The Street - Thu May 29, 7:17AM CDT
Shares of Celgene (CELG) are lower after J.P. Morgan (JPM) downgraded the stock to 'neutral' from 'overweight' and lowered its price target to $170. from $180.

Breakthrough Innovation for Animal Health, Upcoming Conference Presentations, and New Treatment Options for Patients - Analyst Notes on Merck, Actavis, Celgene, Bristol-Myers Squibb and GSK
PR Newswire - Thu May 29, 4:50AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), Bristol-Myers Squibb Co. (NYSE: BMY) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3057-100free.

Cramer: A Market Too Stupid for Words
at The Street - Wed May 28, 10:32AM CDT
It is pretty incredible that identical news can trigger completely different reactions.

After Yesterday's Rally of 3.33% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue May 27, 3:50PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $150.01 to a high of $155.24. Yesterday, the shares gained 3.3%, which took the trading range above the 3-day high of $151.78 on volume of 4.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Celgene Rises 3.33% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue May 27, 3:49PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $150.01 to a high of $155.24. Yesterday, the shares gained 3.3%, which took the trading range above the 3-day high of $151.78 on volume of 4.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

3 Health Care Stocks Nudging The Sector Higher
at The Street - Tue May 27, 12:02PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.

2014 Value Investor 500: The Full List
Dan Dzombak, The Motley Fool - Motley Fool - Sat May 24, 8:01AM CDT
The Value Investor 500 is my attempt to highlight the top 500 publicly traded companies in the U.S. To construct a quality-based list of the top 500 companies in the U.S., I focused on what's really important for investors to pay attention to: ...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 479

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 354

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 122

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 298

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 225

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 292

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 638

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading

Top 5 Most Recently Viewed Articles

Zenarate Achieves Remarkable Growth, Securing Top Technology Honors

Updated Category News Views 231

Zenarate's Impressive Achievement in the Fast-Growing Tech Sector Zenarate, a leading platform focused on enhancing human and AI agent performance, has made waves in the tech industry with its exceptional ranking. With a remarkable growth of 496%, Zenarate has earned the prestigious recognition as the 165th fastest-growing company on the Deloitte Technology Fast 500™...

Continue Reading
GitLab Inc. Investors Encouraged to Participate in Class Action

Updated Category News Views 64

Important Class Action Opportunity for GitLab Inc. Investors GitLab Inc. shareholders are facing a critical moment, with a significant class action opportunity emerging due to recent events. Robbins Geller Rudman & Dowd LLP has made a vital announcement urging investors who bought GitLab securities during specific dates to come forward. This class action lawsuit, known as...

Continue Reading
Transforming $1000 into Significant Wealth with EME Investment

Updated Category News Views 261

Transform Your Investment Journey with EMCOR Group Investing wisely is a journey that can lead to fruitful rewards, especially when considering the historical performance of a stock. EMCOR Group (EME) is a fine example, having shown impressive growth over the past 15 years. If one were to invest $1000 in EME back then, they would be pleasantly surprised by today's...

Continue Reading
Brown & Brown, Inc. Declares Regular Quarterly Dividend Payment

Updated Category News Views 199

Brown & Brown, Inc. Dividends: Commitment to Shareholders Brown & Brown, Inc. (NYSE: BRO), an established insurance brokerage firm, recently made headlines with the announcement of a quarterly cash dividend of $0.15 per share. This decision was made public by the company's board of directors, illustrating their ongoing commitment to delivering value to their shareholders....

Continue Reading
OCS Finalizes Landmark Acquisition of EMCOR UK for Growth

Updated Category News Views 251

OCS Completes Acquisition of EMCOR UK OCS has officially completed its acquisition of EMCOR UK, marking a significant milestone in the facilities management sector. This strategic move follows the rigorous UK regulatory process, enabling OCS to merge with one of the largest hard services-led businesses in the region. The integration is expected to leverage the extensive...

Continue Reading